As such, gemtuzumab ozogamicin, a CD33-targeted monoclonal antibody conjugated to the cytotoxic agent ozogamicin was approved by the FDA as a targeted therapy for AML. The gene discussed is CD33; the disease is acute myeloid leukemia.